SynthesisBMC cardiovascular disorders2026
Preventive and therapeutic effects of ginsenosides on myocardial ischemia-reperfusion injury in animal models: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMyocardial ischemia-reperfusion injury (MIRI) markedly impairs cardiac functional recovery and represents a major determinant of adverse outcomes in patients with ischemic heart disease. Ginsenosides, the principal bioactive constituents of ginseng, exert significant cardioprotection against MIRI. This review systematically summarizes and analyzes in vivo (animal) studies to clarify the efficacy and underlying mechanisms of ginsenosides in MIRI.
methodsThe PubMed, EMbase, Web of Science, Cochrane Library, CNKI, WanFang, and Cqvip databases were systematically searched from inception to 31 July 2024. In vivo studies evaluating ginsenosides pretreatment or post-treatment in models of MIRI were identified. Outcome measures comprised myocardial infarct size and indices of hemodynamic performance, myocardial injury, apoptosis, inflammation, and oxidative stress. A meta-analysis was conducted with RevMan 5.4 and Stata/MP 14.0.
resultsThirty-four eligible articles encompassing 505 experimental animals were included. Funnel plots, Egger's tests, and sensitivity analyses confirmed the robustness of the findings. Compared with controls, ginsenosides treatment significantly reduced myocardial infarct size and improved hemodynamic indices (P < 0.0001). Ginsenosides also attenuated MIRI-induced elevations of lactate dehydrogenase, creatine kinase-MB, creatine kinase, malondialdehyde, tumor necrosis factor-α, interleukin-6, interleukin-1β, and cardiomyocyte apoptosis (P < 0.0001). Subgroup analysis further revealed that pre-ischemic ginsenosides administration conferred greater protection than post-reperfusion treatment.
conclusionGinsenosides play a significant role in the prevention and treatment of MIRI. Ginsenosides can reduce the area of myocardial infarction and improve myocardial damage through anti-inflammatory, antioxidative stress, anti-apoptosis, regulation of autophagy, and energy metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.